These findings reveal on one hand that reduced genomic 5-hmc is a marker of ATLL aggressiveness and on the other hand that TET2 downregulation rather than TET2 mutations is the main mechanism for 5-hmc loss in ATLL tumor cells. This evidence concerns the gene TET2 and adult T-cell leukemia/lymphoma.